Informed Consent
Item
1. written informed consent must be obtained from all patients before entry into the study
boolean
C0021430 (UMLS CUI [1])
Multiple Myeloma
Item
2. patients must have a diagnosis of myeloma
boolean
C0026764 (UMLS CUI [1])
Inclusion Criteria
Item
3. patients must meet one of the following criteria:
boolean
C1512693 (UMLS CUI [1])
Relapse or progression
Item
myeloma has relapsed, progressed, or failed to respond after at least one prior course of therapy.
boolean
C0277556 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
Response to treatment
Item
myeloma has responded partially to initial therapy but neither a complete nor a near-complete response has developed after at least 3 cycles or months of initial therapy.
boolean
C0521982 (UMLS CUI [1])
Myeloma at high risk
Item
myeloma has high-risk features
boolean
C0332167 (UMLS CUI [1,1])
C0026764 (UMLS CUI [1,2])
Measurable disease
Item
4. patients must have measurable disease on study entry.
boolean
C1513041 (UMLS CUI [1])
Age
Item
5. patients must be between ages 18-80 (inclusive).
boolean
C0001779 (UMLS CUI [1])
Organ function
Item
6. patients should have adequate vital organ function.
boolean
C0678852 (UMLS CUI [1])
ECOG performance status
Item
7. ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Contraceptive methods
Item
8. women of child-bearing potential (wocbp) and their spouses or partners must be willing to use adequate contraception for the duration of the active treatment phase of the study and for at least 4 months after the last dose of chemotherapy. in addition, contraceptive measures must be continued as long as the patient remains on maintenance thalidomide in accordance with the steps program.
boolean
C0700589 (UMLS CUI [1])
Exclusion Criteria
Item
key exclusion criteria
boolean
C0680251 (UMLS CUI [1])
Exclusion criteria specification
Item
subjects who meet any of the following criteria cannot be enrolled in the study:
boolean
C0680251 (UMLS CUI [1,1])
C2348235 (UMLS CUI [1,2])
Gynaecological status
Item
1. pregnant or nursing females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HIV, HTLV
Item
2. hiv, htlv-1/2 seropositivity
boolean
C0019682 (UMLS CUI [1])
C0086427 (UMLS CUI [2])
Myelodysplasia
Item
3. known history of myelodysplasia
boolean
C0026985 (UMLS CUI [1])
Chronic active hepatitis or liver cirrhosis
Item
4. known history of chronic active hepatitis or liver cirrhosis (if suspected by laboratory studies, should be confirmed by liver biopsy).
boolean
C0520463 (UMLS CUI [1])
C0023890 (UMLS CUI [2])
Active Hepatitis B
Item
5. active hepatitis b
boolean
C0019163 (UMLS CUI [1])
Autotransplant or allogeneic transplant
Item
6. prior autotransplant or allogeneic transplant
boolean
C0040736 (UMLS CUI [1])
Myeloma therapy
Item
7. more than 4 distinct, prior courses of therapy for myeloma
boolean
C0026764 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
Severe autoimmune disease
Item
8. history of severe autoimmune disease requiring steroids or other immunosuppressive treatments.
boolean
C0004364 (UMLS CUI [1])
connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis
Item
9. active immune-mediated diseases including: connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis.
boolean
C0009782 (UMLS CUI [1])
C0042164 (UMLS CUI [2])
C0036202 (UMLS CUI [3])
C0021390 (UMLS CUI [4])
C0026769 (UMLS CUI [5])
Comorbidity
Item
10. evidence or history of other significant cardiac, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease which might increase the risks of participating in the study
boolean
C0009488 (UMLS CUI [1])
Infection
Item
11. active bacterial, viral or fungal infections.
boolean
C0009450 (UMLS CUI [1])